Help Desk
10 Am-7 Pm (Mon-Sat)
Contact
+91 728 787 4503
cancermeds-list
cancermeds-noimage

ETOSID INJ 100 MG 5 ML ( PC , 1 )

Manufactured by : Cipla Limited

. 172.00/- . 201.87/- 14.8 % OFF You Save : . 29.87
Availability : In stock

DESCRIPTION

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [PubChem]

CATEGORIES

Antineoplastic Agents Immunosuppressive Agents Antineoplastic Agents, Phytogenic Tubulin Modulators Keratolytic Agents Topoisomerase II Inhibitors Antineoplastic and Immunomodulating Agents Podophyllotoxin Derivatives Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inducers Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inducers CYP2E1 Inhibitors CYP2E1 Inducers CYP2E1 Inducers (strong) CYP3A4 Inhibitors Combined Inhibitors of CYP3A4 and P-glycoprotein

CHEMICAL FORMULA

C29H32O13

COMPOSITION

Etoposide 100 MG

INDICATION

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

PHARMACODYNAMICS

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

MECHANISM

Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division. Inhibition of the topoisomerase II alpha isoform results in the anti-tumour activity of etoposide. The drug is also capable of inhibiting the beta isoform but inhibition of this target is not associated with the anti-tumour activity. It is instead associated with the carcinogenic effect.

ABSORPTION

Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50% (range of 25% - 75%). Cmax and AUC values for orally administered etoposide capsules display intra- and inter-subject variability. There is no evidence of first-pass effect for etoposide.

VOLUME DISTRIBUTION

The disposition of etoposide is a biphasic process with a distribution half-life of 1.5 hours. It does not cross into cerebrospinal fluid well. Volume of distribution, steady state = 18 – 29 L.

METABOLISM

Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine. Etoposide also undergoes glutathione and glucuronide conjugation which are catalyzed by GSTT1/GSTP1 and UGT1A1, respectively. Prostaglandin synthases are also responsible for the conversion of etoposide to O-demethylated metabolites (quinone).

ROUTE ELIMINATION

Etoposide is cleared by both renal and nonrenal processes, i.e., metabolism and biliary excretion. Glucuronide and/or sulfate conjugates of etoposide are also excreted in human urine. Biliary excretion of unchanged drug and/or metabolites is an important route of etoposide elimination as fecal recovery of radioactivity is 44% of the intravenous dose. 56% of the dose was in the urine, 45% of which was excreted as etoposide.

HALF LIFE

4-11 hours

TOXICITY

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

FOOD INTERACTIONS

Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can decrease serum levels of this product.

SIDE EFFECTS

Chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu. Anemia, low white blood cell count, and low platelet count. Feeling tired or weak. Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. Loose stools (diarrhea). Irritation or swelling where the shot was given. Hair loss. Hair most often grows back when this drug is stopped. May not be able to get pregnant. Flushing and low blood pressure can happen if the shot is given too fast. Unsafe allergic effects may rarely happen.